
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-A

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934**

ASLAN Pharmaceuticals Limited

(Exact name of registrant as specified in its charter)

The Cayman Islands
(State or other jurisdiction of
incorporation or organization)

Not applicable
(I.R.S. Employer
Identification No.)

83 Clemenceau Avenue #12-03 UE Square
Singapore 239920
(Address of principal executive offices)

Not applicable
(Zip code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class
to be so registered

Name of each exchange on which
each class is to be registered

**American Depositary Shares, each representing five ordinary shares, par
value NT\$10 per ordinary share**

The Nasdaq Stock Market LLC

Ordinary shares, par value NT\$10 per ordinary share*

The Nasdaq Stock Market LLC*

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A. (c) or (e), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A. (d) or (e), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **333-223920**

Securities to be registered pursuant to Section 12(g) of the Act: None.

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

Item 1. Description of Registrant's Securities to be Registered.

ASLAN Pharmaceuticals Limited (the "Company") hereby incorporates by reference (a) the description of its ordinary shares, par value NT\$10 per ordinary share, contained under the heading "*Description of Share Capital and Governing Documents*," (b) the description of its American Depositary Shares, each representing five ordinary shares, par value NT\$10 per ordinary share, contained under the heading "*Description of American Depositary Shares*" and (c) the information set forth under the heading "*Material Income Tax Considerations*," in each case, in the Company's Registration Statement on Form F-1 (333-223920), as originally filed with the Securities and Exchange Commission on March 26, 2018, as amended from time to time (the "Registration Statement"). In addition, all of the above-referenced descriptions included in any prospectus forming a part of the Registration Statement subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, shall be deemed to be incorporated by reference herein.

Item 2. Exhibits.

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

ASLAN Pharmaceuticals Limited

Date: April 30, 2018

By: /s/ Carl Firth

Name: Carl Firth, Ph.D.

Title: Chief Executive Officer and Chairman